Pharmaceutical-grade Ecopipam O-β-D-glucuronide is supplied as a Pharma Grade API for tablet, capsule, granule, and injection processing, covering both oral and injectable administration routes. The product is released under the production-stock identifier EPG-β-D-GlcA-PG/OI; this identifier is a lot-linked material code that connects the certificate of analysis to the master batch record, impurity profile, and reference standard inventory. It is supplied as a non-sterile solid for downstream formulation into tablets, capsules, granules, and injectable intermediates, with separate release criteria for oral non-sterile use and injectable-grade processing. The β-D-glucuronide moiety introduces a carboxylic acid residue and multiple hydroxyl groups, changing aqueous solubility, dissolution rate, solid-state hygroscopicity, and particle surface energy relative to the parent free base and methylated or sulfated metabolites. Identification relies on retention-time agreement with a qualified reference standard by high-performance liquid chromatography and infrared absorption according to USP <197>; assay is reported on anhydrous and solvent-free basis. Impurity, residual solvent, and elemental impurity control are aligned to ICH Q3A, ICH Q3C, and ICH Q3D. Published single-crystal X-ray diffraction data for this specific glucuronide are limited; therefore, polymorph designation is controlled by differential scanning calorimetry and X-ray powder diffraction against the approved production batch rather than by absolute crystal-structure assignment.

Which release limits and compendial procedures define the injectable-grade boundary?

For the injectable-grade boundary, the differentiating tests are bacterial endotoxin, subvisible particulate matter in the finished solution, and pre-filtration bioburden. The API itself is not usually a final sterile article; instead, the formulation is sterilised by aseptic filtration or terminal sterilisation after API dissolution. The API specification for injectable use therefore adds a bacterial endotoxin limit expressed in endotoxin units per milligram of API, determined by USP <85>. The limit is dose-linked: if the maximum adult dose is projected to be 100 mg/day, the endotoxin limit is calculated from 5 EU/kg/h divided by the maximum dose per kilogram per hour, expressed as EU/mg. Because the β-D-glucuronide linkage can be sensitive to the temperature and pH conditions of terminal sterilisation, filter compatibility and chemical stability of the dissolved conjugate often become the more restrictive factors. Table 1 summarises the release parameter matrix.

Routine release of oral-grade material excludes bacterial endotoxin but adds microbial limits under USP <61> and USP <62>. For injectable processing, the equivalent microbial control is achieved by pre-filtration bioburden monitoring and sterilising-grade filtration; the subvisible particle load in the finished injection is measured by USP <788> and must meet ≤6000 particles/container ≥10 μm and ≤600 particles/container ≥25 μm for the targeted fill volume.

Stability-linked processing constraints for tablets, capsules, granules, and injectable solutions

The β-D-glucuronide linkage is susceptible to acid-catalysed and enzymatic hydrolysis, while the aglycone may undergo oxidation if exposed to oxidising excipients. Forced-degradation studies are run under ICH Q1A conditions: 0.1 N HCl at 60°C, 0.1 N NaOH at 60°C, 3% H₂O₂, and photostability per ICH Q1B. These studies define the pH range for aqueous granulation and compounding. If the glucuronide shows more than 5.0% degradation in acid after 24 h, delayed-release or enteric coating may be required for oral dosage forms, but no assumption should be made without batch data; published data for this specific configuration are limited. Acyl glucuronides are more prone to intramolecular acyl migration and covalent protein adduct formation than ether-linked phenolic glucuronides. Ecopipam O-β-D-glucuronide is a phenolic O-β-D-glucuronide, so the primary chemical risk is hydrolytic release of ecopipam rather than acyl migration. Therefore, injection solutions are compounded at low temperature, and pH is adjusted to a range that balances solubility and linkage stability. Terminal heat sterilisation may be unsuitable if forced-degradation data demonstrate more than 0.5% aglycone formation at the sterilisation F₀; aseptic filtration through 0.22 µm PVDF or polyethersulfone membrane is then used, with filter integrity testing by diffusion or bubble point per filter manufacturer method.

For injectable processing, the API is dissolved in a vehicle selected for compatibility with the ionisable carboxylic acid group. If the vehicle contains phosphate buffer and the terminal pH exceeds the pKa of the glucuronic acid residue, the conjugate remains negatively charged and solubility is increased, but chemical stability may still be limited by base-catalysed degradation. The dissolved API is passed through a bioburden-reduction filter before sterile filtration. Prefiltration bioburden is controlled below 10 CFU/100 mL as a commonly applied process limit; the limit is verified by membrane filtration and plate count. The final filtered solution is filled under Grade A aseptic conditions; line setup includes a 0.22 µm sterilising-grade filter, with pre-use integrity testing. If the product is lyophilised, collapse temperature is measured by freeze-dry microscopy or differential scanning calorimetry, and the primary drying shelf temperature is set below the measured collapse temperature. Published data for this specific conjugate are limited, so cycle development cannot be transferred from the free base formulation.

Dry mixing and direct compression of the glucuronide are constrained by particle-size distribution and flow behaviour. Because the material may exhibit cohesive flow due to the polar glucuronic acid surface, a powder flow measurement by USP <1174> is performed on the development batch. If compressibility index exceeds 30% or Hausner ratio exceeds 1.40, the formulation is shifted to wet granulation or roller compaction. Roller compaction equipment such as a Gerteis MINI-PACTOR or Alexanderwerk WP120 is used with gap setting and compaction force adjusted to produce ribbon solid fraction between 0.55 and 0.70; published roller-compaction parameters for this specific glucuronide are limited, so transfer from placebo runs requires direct measurement. For granules intended for tablet or capsule filling, loss on drying after fluid-bed drying is monitored by USP <731>, and moisture is kept below the value that causes glass transition depression and sticking. Granulation fluid volume is specified by torque or impeller power consumption in a high-shear granulator; end point is determined by wet mass consistency, not by fixed time. Drying in a fluid-bed dryer with inlet air temperature no greater than the value shown to produce ≤0.2% aglycone increase in forced-degradation studies is preferred. Milling of dried granules through a 0.5 mm or 0.8 mm screen produces a granule size distribution suitable for encapsulation. These process parameters are qualified by measuring content uniformity of the blend per USP <905> and by monitoring moisture by Karl Fischer USP <921>.

Batch-to-batch variance in particle size distribution and specific surface area is mitigated by setting release limits for D10, D50, and D90 by laser diffraction. If the D90 exceeds the qualification range, dry milling may be required before formulation; if the D10 is too small, static charge and dusting during capsule filling may increase. Surface area measured by Brunauer-Emmett-Teller gas adsorption is reported if dissolution is surface-controlled; published data for this specific glucuronide are limited. The batch record requires in-process controls for blend uniformity according to USP <905> and for moisture according to USP <921> before compression or encapsulation.

When the O-β-D-glucuronide conjugate replaces ecopipam free base, sulfate ester, or methyl ether in formulation development

Substitution of Ecopipam O-β-D-glucuronide for ecopipam free base changes dissolution, permeability, and in vivo exposure. The free base is a lipophilic molecule with high passive permeability, whereas the glucuronide conjugate is a polar, acidic molecule with lower log P and greater aqueous solubility. This difference is measurable in shake-flask log P or chromatographic hydrophobicity index; exact values for this specific conjugate are not available in publicly accessible monographs. The sulfate conjugate has a different charge and a smaller solvation shell than the glucuronide; the methyl ether lacks the ionisable acid and has lower water affinity. Therefore, the glucuronide cannot be treated as a simple diluent substitution in a tablet or capsule formula. Dissolution testing per USP <711> should be developed with the formulated product and a discriminatory medium. If the glucuronide is used as a prodrug or as an active metabolite, the conversion to ecopipam in the gastrointestinal tract or plasma depends on β-glucuronidase activity; consequently, oral bioavailability is influenced by intestinal microbiota and may show food and disease-state variability. Published data for this specific configuration are limited.

The product is not interchangeable with ecopipam base monographs. If a monograph for ecopipam lists O-β-D-glucuronide as a specified impurity or metabolite, release of the glucuronide as an API requires a separate impurity profile and acceptance criteria. Residual parent ecopipam is quantified as a process-related impurity with a specification limit justified by toxicological data. The material's difference from the parent is also reflected in storage: the glucuronide may be stored in a desiccator at controlled room temperature, while the free base may require protection from light but less stringent humidity control. Stability protocols follow ICH Q1A and ICH Q1B; for the injectable solution, a separate photostability assessment is required if the solution is light-sensitive.

Analytical differentiation from ecopipam free base and the α-epimer or β-sulfate conjugate requires orthogonal methods. A reversed-phase HPLC method using a C18 column and mobile phase buffered at pH 3.0 may separate the polar glucuronide from the less polar free base; the glucuronide elutes earlier under acidic conditions. Because the anomeric purity of the β-D-glucuronide is critical, the product specification includes an HPLC method capable of separating α and β epimers. A resolution of ≥1.5 between α- and β-anomer peaks is targeted; if this is not achieved, a polar-organic or HILIC mobile phase is used. Structural confirmation of the O-β-D-glucosidic linkage uses 1H NMR and 13C NMR; the anomeric proton of β-D-glucuronide appears as a doublet with coupling constant J = 7–9 Hz, while the α-anomer exhibits a smaller coupling constant. This is consistent with carbohydrate stereochemistry and allows detection of anomeric impurity below the reporting threshold.

Compared with a simple physical mixture of ecopipam free base and glucuronic acid, the O-β-D-glucuronide is a defined covalent conjugate and not a salt or co-crystal. This distinction changes the phase behaviour: a physical mixture may show two melting endotherms and dissolution dominated by the free base, while the conjugate exhibits a single phase with altered thermal events. Differential scanning calorimetry of the product is used to confirm the absence of free glucuronic acid or free ecopipam; the acceptance criterion is absence of the free base endothermic peak at its characteristic temperature, subject to the reference batch. The product also differs from the sodium salt of the glucuronide, which may be produced in situ during pH adjustment for injection; the sodium salt has higher water uptake and may require lower humidity handling.

Cleaning of contact surfaces after processing the glucuronide must address the residual API's polarity and potential hydrogen bonding to stainless steel. The cleaning validation protocol uses swab sampling from product-contact surfaces, with an acceptance limit based on the maximum allowable carryover. A conservative limit is 10 ppm in the next product or 1/1000th of the lowest therapeutic dose, whichever is lower. Detection is by HPLC or total organic carbon; if total organic carbon is used, the limit is expressed as carbon rather than API. Because the glucuronide is water-soluble, warm detergent solutions are usually effective, but residue removal must be confirmed for the interior of the fluid-bed dryer filter bags and for the high-shear granulator bowl seals. Equipment cleaning is performed under 21 CFR 211.67.

Compatibility with common parenteral excipients is assessed by visual inspection, pH, assay, and particle size after storage at 25°C and 2–8°C. If the solution is stored in a polyvinyl chloride bag, sorption to the bag material should be measured; because the glucuronide is hydrophilic, sorption is expected to be lower than for the free base, but the effect must be confirmed. For infusions, the diluted solution is tested for subvisible particles by USP <788> and for assay by HPLC at the proposed administration time. No data support material compatibility beyond the specific container-closure system documented in the regulatory file.